NEW YORK, NY-Reshma Kewalramani, the Mumbai-born CEO of Vertex Pharmaceuticals, has been named one of the 100 Most Powerful ...

The RMR Group (Nasdaq: RMR) today announced on behalf of its managed joint venture that it has facilitated a $1.0 billion five-year, interest-only fixed rate mortgage financing with a weighted-average ...

Strand Therapeutics announced on Thursday that it landed a $153 million Series B funding led by Kinnevik. The company’s ...

Vertex's late-stage pipeline also gives investors several lottery tickets with great odds. The drugmaker is evaluating ...

Vertex Pharmaceuticals recently reported a significant revenue jump to $2,965 million in Q2 2025. Despite this success, the ...

Propel Health Communications, a 2025 MM+M Agency 100 honoree, hired Christopher Thorn as SVP, creative director and Lauren ...

Shantanu Narayen, Reshma Kewalramani, Neal Mohan, Mukesh Ambani and Gautam Adani also make the Fortune 100 Most Powerful ...

Vertex Pharmaceuticals nosedived on Tuesday to hit a new all-time low following the termination of a clinical trial for an ...

From tariffs to drug pricing to the FDA, biopharma CEOs find themselves pulled into policy discussions on this year’s second quarter earnings calls.

Mallinckrodt plc today announced the appointment of Christiana Stamoulis as President and Chief Financial Officer, effective September 22, 2025. Ms. Stamoulis, currently the EVP and Chief Financial ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Vertex Pharmaceuticals Inc. fell after an experimental pain drug failed to provide post-surgery benefits and US regulators ...